nodes	percent_of_prediction	percent_of_DWPC	metapath
Ibandronate—FDPS—nephron tubule—kidney cancer	0.00795	0.19	CbGeAlD
Ibandronate—FDPS—renal system—kidney cancer	0.00723	0.172	CbGeAlD
Ibandronate—FDPS—kidney—kidney cancer	0.00699	0.167	CbGeAlD
Ibandronate—FDPS—cortex of kidney—kidney cancer	0.0068	0.162	CbGeAlD
Ibandronate—Zoledronate—CA2—kidney cancer	0.0065	0.673	CrCbGaD
Ibandronate—FDPS—gonad—kidney cancer	0.00648	0.155	CbGeAlD
Ibandronate—FDPS—cardiac atrium—kidney cancer	0.00647	0.154	CbGeAlD
Ibandronate—Risedronate—PTGS2—kidney cancer	0.00316	0.328	CrCbGaD
Ibandronate—Malaise—Paclitaxel—kidney cancer	0.000394	0.000416	CcSEcCtD
Ibandronate—Vertigo—Paclitaxel—kidney cancer	0.000393	0.000414	CcSEcCtD
Ibandronate—Hypersensitivity—Sunitinib—kidney cancer	0.000391	0.000412	CcSEcCtD
Ibandronate—Decreased appetite—Vincristine—kidney cancer	0.00039	0.000412	CcSEcCtD
Ibandronate—Pruritus—Sorafenib—kidney cancer	0.00039	0.000412	CcSEcCtD
Ibandronate—Vomiting—Erlotinib—kidney cancer	0.00039	0.000411	CcSEcCtD
Ibandronate—Musculoskeletal discomfort—Gemcitabine—kidney cancer	0.000388	0.000409	CcSEcCtD
Ibandronate—Gastrointestinal disorder—Vincristine—kidney cancer	0.000388	0.000409	CcSEcCtD
Ibandronate—Fatigue—Vincristine—kidney cancer	0.000387	0.000408	CcSEcCtD
Ibandronate—Rash—Erlotinib—kidney cancer	0.000387	0.000408	CcSEcCtD
Ibandronate—Dermatitis—Erlotinib—kidney cancer	0.000386	0.000407	CcSEcCtD
Ibandronate—Palpitations—Paclitaxel—kidney cancer	0.000386	0.000407	CcSEcCtD
Ibandronate—Insomnia—Gemcitabine—kidney cancer	0.000385	0.000406	CcSEcCtD
Ibandronate—Eye disorder—Capecitabine—kidney cancer	0.000385	0.000406	CcSEcCtD
Ibandronate—Headache—Erlotinib—kidney cancer	0.000384	0.000405	CcSEcCtD
Ibandronate—Pain—Vincristine—kidney cancer	0.000384	0.000405	CcSEcCtD
Ibandronate—Constipation—Vincristine—kidney cancer	0.000384	0.000405	CcSEcCtD
Ibandronate—Pain in extremity—Doxorubicin—kidney cancer	0.000384	0.000405	CcSEcCtD
Ibandronate—Osteoarthritis—Doxorubicin—kidney cancer	0.000384	0.000405	CcSEcCtD
Ibandronate—Paraesthesia—Gemcitabine—kidney cancer	0.000383	0.000403	CcSEcCtD
Ibandronate—Cardiac disorder—Capecitabine—kidney cancer	0.000382	0.000403	CcSEcCtD
Ibandronate—Asthenia—Sunitinib—kidney cancer	0.000381	0.000402	CcSEcCtD
Ibandronate—Nausea—Vinblastine—kidney cancer	0.000379	0.0004	CcSEcCtD
Ibandronate—Migraine—Doxorubicin—kidney cancer	0.000378	0.000398	CcSEcCtD
Ibandronate—Nausea—Everolimus—kidney cancer	0.000378	0.000398	CcSEcCtD
Ibandronate—Diarrhoea—Sorafenib—kidney cancer	0.000378	0.000398	CcSEcCtD
Ibandronate—Hypertension—Paclitaxel—kidney cancer	0.000377	0.000398	CcSEcCtD
Ibandronate—Pruritus—Sunitinib—kidney cancer	0.000376	0.000396	CcSEcCtD
Ibandronate—Angiopathy—Capecitabine—kidney cancer	0.000374	0.000394	CcSEcCtD
Ibandronate—Immune system disorder—Capecitabine—kidney cancer	0.000372	0.000392	CcSEcCtD
Ibandronate—Arthralgia—Paclitaxel—kidney cancer	0.000372	0.000392	CcSEcCtD
Ibandronate—Chest pain—Paclitaxel—kidney cancer	0.000372	0.000392	CcSEcCtD
Ibandronate—Myalgia—Paclitaxel—kidney cancer	0.000372	0.000392	CcSEcCtD
Ibandronate—Mediastinal disorder—Capecitabine—kidney cancer	0.000371	0.000391	CcSEcCtD
Ibandronate—Anxiety—Paclitaxel—kidney cancer	0.000371	0.000391	CcSEcCtD
Ibandronate—Face oedema—Doxorubicin—kidney cancer	0.000371	0.000391	CcSEcCtD
Ibandronate—Decreased appetite—Gemcitabine—kidney cancer	0.00037	0.00039	CcSEcCtD
Ibandronate—Hypersensitivity—Dactinomycin—kidney cancer	0.00037	0.00039	CcSEcCtD
Ibandronate—Chills—Capecitabine—kidney cancer	0.00037	0.00039	CcSEcCtD
Ibandronate—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	0.000369	0.00039	CcSEcCtD
Ibandronate—Gastrointestinal disorder—Gemcitabine—kidney cancer	0.000368	0.000388	CcSEcCtD
Ibandronate—Discomfort—Paclitaxel—kidney cancer	0.000368	0.000388	CcSEcCtD
Ibandronate—Fatigue—Gemcitabine—kidney cancer	0.000367	0.000387	CcSEcCtD
Ibandronate—Gastrointestinal pain—Vincristine—kidney cancer	0.000367	0.000387	CcSEcCtD
Ibandronate—Dizziness—Sorafenib—kidney cancer	0.000365	0.000385	CcSEcCtD
Ibandronate—Pain—Gemcitabine—kidney cancer	0.000364	0.000384	CcSEcCtD
Ibandronate—Constipation—Gemcitabine—kidney cancer	0.000364	0.000384	CcSEcCtD
Ibandronate—Nausea—Erlotinib—kidney cancer	0.000364	0.000384	CcSEcCtD
Ibandronate—Alopecia—Capecitabine—kidney cancer	0.000364	0.000384	CcSEcCtD
Ibandronate—Dry mouth—Paclitaxel—kidney cancer	0.000364	0.000384	CcSEcCtD
Ibandronate—Diarrhoea—Sunitinib—kidney cancer	0.000363	0.000383	CcSEcCtD
Ibandronate—Mental disorder—Capecitabine—kidney cancer	0.000361	0.000381	CcSEcCtD
Ibandronate—Asthenia—Dactinomycin—kidney cancer	0.000361	0.00038	CcSEcCtD
Ibandronate—Blood creatinine increased—Doxorubicin—kidney cancer	0.00036	0.000379	CcSEcCtD
Ibandronate—Malnutrition—Capecitabine—kidney cancer	0.000359	0.000378	CcSEcCtD
Ibandronate—Erythema—Capecitabine—kidney cancer	0.000359	0.000378	CcSEcCtD
Ibandronate—Anaphylactic shock—Paclitaxel—kidney cancer	0.000357	0.000376	CcSEcCtD
Ibandronate—Abdominal pain—Vincristine—kidney cancer	0.000355	0.000374	CcSEcCtD
Ibandronate—Body temperature increased—Vincristine—kidney cancer	0.000355	0.000374	CcSEcCtD
Ibandronate—Infection—Paclitaxel—kidney cancer	0.000354	0.000374	CcSEcCtD
Ibandronate—Flatulence—Capecitabine—kidney cancer	0.000353	0.000373	CcSEcCtD
Ibandronate—Dysgeusia—Capecitabine—kidney cancer	0.000351	0.00037	CcSEcCtD
Ibandronate—Dizziness—Sunitinib—kidney cancer	0.000351	0.00037	CcSEcCtD
Ibandronate—Feeling abnormal—Gemcitabine—kidney cancer	0.000351	0.00037	CcSEcCtD
Ibandronate—Shock—Paclitaxel—kidney cancer	0.000351	0.00037	CcSEcCtD
Ibandronate—Vomiting—Sorafenib—kidney cancer	0.000351	0.00037	CcSEcCtD
Ibandronate—Abdominal pain upper—Doxorubicin—kidney cancer	0.000351	0.00037	CcSEcCtD
Ibandronate—Nervous system disorder—Paclitaxel—kidney cancer	0.00035	0.000369	CcSEcCtD
Ibandronate—Rash—Sorafenib—kidney cancer	0.000348	0.000367	CcSEcCtD
Ibandronate—Dermatitis—Sorafenib—kidney cancer	0.000348	0.000366	CcSEcCtD
Ibandronate—Back pain—Capecitabine—kidney cancer	0.000347	0.000366	CcSEcCtD
Ibandronate—Breast disorder—Doxorubicin—kidney cancer	0.000347	0.000366	CcSEcCtD
Ibandronate—Skin disorder—Paclitaxel—kidney cancer	0.000346	0.000365	CcSEcCtD
Ibandronate—Headache—Sorafenib—kidney cancer	0.000346	0.000364	CcSEcCtD
Ibandronate—Muscle spasms—Capecitabine—kidney cancer	0.000345	0.000364	CcSEcCtD
Ibandronate—Hyperhidrosis—Paclitaxel—kidney cancer	0.000345	0.000364	CcSEcCtD
Ibandronate—Diarrhoea—Dactinomycin—kidney cancer	0.000344	0.000363	CcSEcCtD
Ibandronate—Nasopharyngitis—Doxorubicin—kidney cancer	0.000343	0.000362	CcSEcCtD
Ibandronate—Gastritis—Doxorubicin—kidney cancer	0.00034	0.000358	CcSEcCtD
Ibandronate—Vomiting—Sunitinib—kidney cancer	0.000338	0.000356	CcSEcCtD
Ibandronate—Body temperature increased—Gemcitabine—kidney cancer	0.000337	0.000355	CcSEcCtD
Ibandronate—Rash—Sunitinib—kidney cancer	0.000335	0.000353	CcSEcCtD
Ibandronate—Dermatitis—Sunitinib—kidney cancer	0.000334	0.000353	CcSEcCtD
Ibandronate—Ill-defined disorder—Capecitabine—kidney cancer	0.000333	0.000351	CcSEcCtD
Ibandronate—Headache—Sunitinib—kidney cancer	0.000333	0.000351	CcSEcCtD
Ibandronate—Asthma—Doxorubicin—kidney cancer	0.000332	0.00035	CcSEcCtD
Ibandronate—Dysphagia—Doxorubicin—kidney cancer	0.000332	0.00035	CcSEcCtD
Ibandronate—Influenza—Doxorubicin—kidney cancer	0.000332	0.00035	CcSEcCtD
Ibandronate—Anaemia—Capecitabine—kidney cancer	0.000331	0.000349	CcSEcCtD
Ibandronate—Hypersensitivity—Vincristine—kidney cancer	0.000331	0.000349	CcSEcCtD
Ibandronate—Nausea—Sorafenib—kidney cancer	0.000328	0.000346	CcSEcCtD
Ibandronate—Musculoskeletal discomfort—Paclitaxel—kidney cancer	0.000325	0.000343	CcSEcCtD
Ibandronate—Malaise—Capecitabine—kidney cancer	0.000323	0.000341	CcSEcCtD
Ibandronate—Insomnia—Paclitaxel—kidney cancer	0.000323	0.00034	CcSEcCtD
Ibandronate—Vertigo—Capecitabine—kidney cancer	0.000322	0.00034	CcSEcCtD
Ibandronate—Asthenia—Vincristine—kidney cancer	0.000322	0.00034	CcSEcCtD
Ibandronate—Paraesthesia—Paclitaxel—kidney cancer	0.00032	0.000338	CcSEcCtD
Ibandronate—Vomiting—Dactinomycin—kidney cancer	0.00032	0.000337	CcSEcCtD
Ibandronate—Bronchitis—Doxorubicin—kidney cancer	0.000319	0.000336	CcSEcCtD
Ibandronate—Palpitations—Capecitabine—kidney cancer	0.000317	0.000334	CcSEcCtD
Ibandronate—Rash—Dactinomycin—kidney cancer	0.000317	0.000334	CcSEcCtD
Ibandronate—Nausea—Sunitinib—kidney cancer	0.000315	0.000332	CcSEcCtD
Ibandronate—Dyspepsia—Paclitaxel—kidney cancer	0.000314	0.000331	CcSEcCtD
Ibandronate—Decreased appetite—Paclitaxel—kidney cancer	0.00031	0.000327	CcSEcCtD
Ibandronate—Hypertension—Capecitabine—kidney cancer	0.00031	0.000326	CcSEcCtD
Ibandronate—Upper respiratory tract infection—Doxorubicin—kidney cancer	0.000308	0.000325	CcSEcCtD
Ibandronate—Gastrointestinal disorder—Paclitaxel—kidney cancer	0.000308	0.000325	CcSEcCtD
Ibandronate—Fatigue—Paclitaxel—kidney cancer	0.000307	0.000324	CcSEcCtD
Ibandronate—Diarrhoea—Vincristine—kidney cancer	0.000307	0.000324	CcSEcCtD
Ibandronate—Asthenia—Gemcitabine—kidney cancer	0.000306	0.000322	CcSEcCtD
Ibandronate—Arthralgia—Capecitabine—kidney cancer	0.000305	0.000322	CcSEcCtD
Ibandronate—Chest pain—Capecitabine—kidney cancer	0.000305	0.000322	CcSEcCtD
Ibandronate—Myalgia—Capecitabine—kidney cancer	0.000305	0.000322	CcSEcCtD
Ibandronate—Constipation—Paclitaxel—kidney cancer	0.000305	0.000322	CcSEcCtD
Ibandronate—Pain—Paclitaxel—kidney cancer	0.000305	0.000322	CcSEcCtD
Ibandronate—Anxiety—Capecitabine—kidney cancer	0.000304	0.000321	CcSEcCtD
Ibandronate—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	0.000303	0.00032	CcSEcCtD
Ibandronate—Discomfort—Capecitabine—kidney cancer	0.000302	0.000318	CcSEcCtD
Ibandronate—Pruritus—Gemcitabine—kidney cancer	0.000301	0.000318	CcSEcCtD
Ibandronate—Weight decreased—Doxorubicin—kidney cancer	0.0003	0.000316	CcSEcCtD
Ibandronate—Dry mouth—Capecitabine—kidney cancer	0.000299	0.000315	CcSEcCtD
Ibandronate—Nausea—Dactinomycin—kidney cancer	0.000299	0.000315	CcSEcCtD
Ibandronate—Pneumonia—Doxorubicin—kidney cancer	0.000298	0.000314	CcSEcCtD
Ibandronate—Dizziness—Vincristine—kidney cancer	0.000297	0.000313	CcSEcCtD
Ibandronate—Infestation—Doxorubicin—kidney cancer	0.000296	0.000312	CcSEcCtD
Ibandronate—Infestation NOS—Doxorubicin—kidney cancer	0.000296	0.000312	CcSEcCtD
Ibandronate—Feeling abnormal—Paclitaxel—kidney cancer	0.000294	0.00031	CcSEcCtD
Ibandronate—Gastrointestinal pain—Paclitaxel—kidney cancer	0.000292	0.000308	CcSEcCtD
Ibandronate—Diarrhoea—Gemcitabine—kidney cancer	0.000291	0.000307	CcSEcCtD
Ibandronate—Renal failure—Doxorubicin—kidney cancer	0.000291	0.000307	CcSEcCtD
Ibandronate—Infection—Capecitabine—kidney cancer	0.000291	0.000307	CcSEcCtD
Ibandronate—Stomatitis—Doxorubicin—kidney cancer	0.000288	0.000304	CcSEcCtD
Ibandronate—Shock—Capecitabine—kidney cancer	0.000288	0.000304	CcSEcCtD
Ibandronate—Urinary tract infection—Doxorubicin—kidney cancer	0.000288	0.000303	CcSEcCtD
Ibandronate—Nervous system disorder—Capecitabine—kidney cancer	0.000287	0.000303	CcSEcCtD
Ibandronate—Vomiting—Vincristine—kidney cancer	0.000286	0.000301	CcSEcCtD
Ibandronate—Skin disorder—Capecitabine—kidney cancer	0.000284	0.0003	CcSEcCtD
Ibandronate—Sweating—Doxorubicin—kidney cancer	0.000284	0.000299	CcSEcCtD
Ibandronate—Urticaria—Paclitaxel—kidney cancer	0.000283	0.000299	CcSEcCtD
Ibandronate—Rash—Vincristine—kidney cancer	0.000283	0.000299	CcSEcCtD
Ibandronate—Hyperhidrosis—Capecitabine—kidney cancer	0.000283	0.000298	CcSEcCtD
Ibandronate—Dermatitis—Vincristine—kidney cancer	0.000283	0.000298	CcSEcCtD
Ibandronate—Abdominal pain—Paclitaxel—kidney cancer	0.000282	0.000297	CcSEcCtD
Ibandronate—Body temperature increased—Paclitaxel—kidney cancer	0.000282	0.000297	CcSEcCtD
Ibandronate—Headache—Vincristine—kidney cancer	0.000281	0.000297	CcSEcCtD
Ibandronate—Hepatobiliary disease—Doxorubicin—kidney cancer	0.00028	0.000295	CcSEcCtD
Ibandronate—Vomiting—Gemcitabine—kidney cancer	0.000271	0.000286	CcSEcCtD
Ibandronate—Rash—Gemcitabine—kidney cancer	0.000269	0.000283	CcSEcCtD
Ibandronate—Dermatitis—Gemcitabine—kidney cancer	0.000268	0.000283	CcSEcCtD
Ibandronate—Haemoglobin—Doxorubicin—kidney cancer	0.000267	0.000281	CcSEcCtD
Ibandronate—Headache—Gemcitabine—kidney cancer	0.000267	0.000281	CcSEcCtD
Ibandronate—Nausea—Vincristine—kidney cancer	0.000267	0.000281	CcSEcCtD
Ibandronate—Musculoskeletal discomfort—Capecitabine—kidney cancer	0.000267	0.000281	CcSEcCtD
Ibandronate—Haemorrhage—Doxorubicin—kidney cancer	0.000266	0.00028	CcSEcCtD
Ibandronate—Insomnia—Capecitabine—kidney cancer	0.000265	0.000279	CcSEcCtD
Ibandronate—Pharyngitis—Doxorubicin—kidney cancer	0.000264	0.000278	CcSEcCtD
Ibandronate—Paraesthesia—Capecitabine—kidney cancer	0.000263	0.000277	CcSEcCtD
Ibandronate—Hypersensitivity—Paclitaxel—kidney cancer	0.000263	0.000277	CcSEcCtD
Ibandronate—Urinary tract disorder—Doxorubicin—kidney cancer	0.000262	0.000277	CcSEcCtD
Ibandronate—Oedema peripheral—Doxorubicin—kidney cancer	0.000262	0.000276	CcSEcCtD
Ibandronate—Connective tissue disorder—Doxorubicin—kidney cancer	0.000261	0.000275	CcSEcCtD
Ibandronate—Urethral disorder—Doxorubicin—kidney cancer	0.00026	0.000274	CcSEcCtD
Ibandronate—Dyspepsia—Capecitabine—kidney cancer	0.000258	0.000272	CcSEcCtD
Ibandronate—Asthenia—Paclitaxel—kidney cancer	0.000256	0.00027	CcSEcCtD
Ibandronate—Decreased appetite—Capecitabine—kidney cancer	0.000254	0.000268	CcSEcCtD
Ibandronate—Nausea—Gemcitabine—kidney cancer	0.000253	0.000267	CcSEcCtD
Ibandronate—Gastrointestinal disorder—Capecitabine—kidney cancer	0.000253	0.000266	CcSEcCtD
Ibandronate—Fatigue—Capecitabine—kidney cancer	0.000252	0.000266	CcSEcCtD
Ibandronate—Pruritus—Paclitaxel—kidney cancer	0.000252	0.000266	CcSEcCtD
Ibandronate—Pain—Capecitabine—kidney cancer	0.00025	0.000264	CcSEcCtD
Ibandronate—Constipation—Capecitabine—kidney cancer	0.00025	0.000264	CcSEcCtD
Ibandronate—Eye disorder—Doxorubicin—kidney cancer	0.000248	0.000262	CcSEcCtD
Ibandronate—Cardiac disorder—Doxorubicin—kidney cancer	0.000246	0.00026	CcSEcCtD
Ibandronate—Diarrhoea—Paclitaxel—kidney cancer	0.000244	0.000257	CcSEcCtD
Ibandronate—Feeling abnormal—Capecitabine—kidney cancer	0.000241	0.000254	CcSEcCtD
Ibandronate—Angiopathy—Doxorubicin—kidney cancer	0.000241	0.000254	CcSEcCtD
Ibandronate—Immune system disorder—Doxorubicin—kidney cancer	0.00024	0.000253	CcSEcCtD
Ibandronate—Gastrointestinal pain—Capecitabine—kidney cancer	0.000239	0.000252	CcSEcCtD
Ibandronate—Mediastinal disorder—Doxorubicin—kidney cancer	0.000239	0.000252	CcSEcCtD
Ibandronate—Chills—Doxorubicin—kidney cancer	0.000238	0.000251	CcSEcCtD
Ibandronate—Dizziness—Paclitaxel—kidney cancer	0.000236	0.000249	CcSEcCtD
Ibandronate—Alopecia—Doxorubicin—kidney cancer	0.000235	0.000247	CcSEcCtD
Ibandronate—Mental disorder—Doxorubicin—kidney cancer	0.000233	0.000245	CcSEcCtD
Ibandronate—Urticaria—Capecitabine—kidney cancer	0.000233	0.000245	CcSEcCtD
Ibandronate—Body temperature increased—Capecitabine—kidney cancer	0.000231	0.000244	CcSEcCtD
Ibandronate—Abdominal pain—Capecitabine—kidney cancer	0.000231	0.000244	CcSEcCtD
Ibandronate—Malnutrition—Doxorubicin—kidney cancer	0.000231	0.000244	CcSEcCtD
Ibandronate—Erythema—Doxorubicin—kidney cancer	0.000231	0.000244	CcSEcCtD
Ibandronate—Flatulence—Doxorubicin—kidney cancer	0.000228	0.00024	CcSEcCtD
Ibandronate—Vomiting—Paclitaxel—kidney cancer	0.000227	0.000239	CcSEcCtD
Ibandronate—Dysgeusia—Doxorubicin—kidney cancer	0.000226	0.000239	CcSEcCtD
Ibandronate—Rash—Paclitaxel—kidney cancer	0.000225	0.000237	CcSEcCtD
Ibandronate—Dermatitis—Paclitaxel—kidney cancer	0.000225	0.000237	CcSEcCtD
Ibandronate—Back pain—Doxorubicin—kidney cancer	0.000224	0.000236	CcSEcCtD
Ibandronate—Headache—Paclitaxel—kidney cancer	0.000223	0.000236	CcSEcCtD
Ibandronate—Muscle spasms—Doxorubicin—kidney cancer	0.000222	0.000234	CcSEcCtD
Ibandronate—Hypersensitivity—Capecitabine—kidney cancer	0.000216	0.000227	CcSEcCtD
Ibandronate—Ill-defined disorder—Doxorubicin—kidney cancer	0.000214	0.000226	CcSEcCtD
Ibandronate—Anaemia—Doxorubicin—kidney cancer	0.000214	0.000225	CcSEcCtD
Ibandronate—Nausea—Paclitaxel—kidney cancer	0.000212	0.000223	CcSEcCtD
Ibandronate—Asthenia—Capecitabine—kidney cancer	0.00021	0.000221	CcSEcCtD
Ibandronate—Malaise—Doxorubicin—kidney cancer	0.000208	0.00022	CcSEcCtD
Ibandronate—Vertigo—Doxorubicin—kidney cancer	0.000208	0.000219	CcSEcCtD
Ibandronate—Pruritus—Capecitabine—kidney cancer	0.000207	0.000218	CcSEcCtD
Ibandronate—Palpitations—Doxorubicin—kidney cancer	0.000204	0.000215	CcSEcCtD
Ibandronate—Diarrhoea—Capecitabine—kidney cancer	0.0002	0.000211	CcSEcCtD
Ibandronate—Hypertension—Doxorubicin—kidney cancer	0.0002	0.00021	CcSEcCtD
Ibandronate—Arthralgia—Doxorubicin—kidney cancer	0.000197	0.000208	CcSEcCtD
Ibandronate—Chest pain—Doxorubicin—kidney cancer	0.000197	0.000208	CcSEcCtD
Ibandronate—Myalgia—Doxorubicin—kidney cancer	0.000197	0.000208	CcSEcCtD
Ibandronate—Anxiety—Doxorubicin—kidney cancer	0.000196	0.000207	CcSEcCtD
Ibandronate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	0.000195	0.000206	CcSEcCtD
Ibandronate—Discomfort—Doxorubicin—kidney cancer	0.000194	0.000205	CcSEcCtD
Ibandronate—Dizziness—Capecitabine—kidney cancer	0.000194	0.000204	CcSEcCtD
Ibandronate—Dry mouth—Doxorubicin—kidney cancer	0.000192	0.000203	CcSEcCtD
Ibandronate—Anaphylactic shock—Doxorubicin—kidney cancer	0.000189	0.000199	CcSEcCtD
Ibandronate—Infection—Doxorubicin—kidney cancer	0.000187	0.000198	CcSEcCtD
Ibandronate—Vomiting—Capecitabine—kidney cancer	0.000186	0.000196	CcSEcCtD
Ibandronate—Shock—Doxorubicin—kidney cancer	0.000186	0.000196	CcSEcCtD
Ibandronate—Nervous system disorder—Doxorubicin—kidney cancer	0.000185	0.000195	CcSEcCtD
Ibandronate—Rash—Capecitabine—kidney cancer	0.000185	0.000195	CcSEcCtD
Ibandronate—Dermatitis—Capecitabine—kidney cancer	0.000184	0.000194	CcSEcCtD
Ibandronate—Headache—Capecitabine—kidney cancer	0.000183	0.000193	CcSEcCtD
Ibandronate—Skin disorder—Doxorubicin—kidney cancer	0.000183	0.000193	CcSEcCtD
Ibandronate—Hyperhidrosis—Doxorubicin—kidney cancer	0.000182	0.000192	CcSEcCtD
Ibandronate—Nausea—Capecitabine—kidney cancer	0.000174	0.000183	CcSEcCtD
Ibandronate—Musculoskeletal discomfort—Doxorubicin—kidney cancer	0.000172	0.000181	CcSEcCtD
Ibandronate—Insomnia—Doxorubicin—kidney cancer	0.000171	0.00018	CcSEcCtD
Ibandronate—Paraesthesia—Doxorubicin—kidney cancer	0.000169	0.000179	CcSEcCtD
Ibandronate—Dyspepsia—Doxorubicin—kidney cancer	0.000166	0.000175	CcSEcCtD
Ibandronate—Decreased appetite—Doxorubicin—kidney cancer	0.000164	0.000173	CcSEcCtD
Ibandronate—Gastrointestinal disorder—Doxorubicin—kidney cancer	0.000163	0.000172	CcSEcCtD
Ibandronate—Fatigue—Doxorubicin—kidney cancer	0.000163	0.000172	CcSEcCtD
Ibandronate—Constipation—Doxorubicin—kidney cancer	0.000161	0.00017	CcSEcCtD
Ibandronate—Pain—Doxorubicin—kidney cancer	0.000161	0.00017	CcSEcCtD
Ibandronate—Feeling abnormal—Doxorubicin—kidney cancer	0.000155	0.000164	CcSEcCtD
Ibandronate—Gastrointestinal pain—Doxorubicin—kidney cancer	0.000154	0.000163	CcSEcCtD
Ibandronate—Urticaria—Doxorubicin—kidney cancer	0.00015	0.000158	CcSEcCtD
Ibandronate—Body temperature increased—Doxorubicin—kidney cancer	0.000149	0.000157	CcSEcCtD
Ibandronate—Abdominal pain—Doxorubicin—kidney cancer	0.000149	0.000157	CcSEcCtD
Ibandronate—Hypersensitivity—Doxorubicin—kidney cancer	0.000139	0.000147	CcSEcCtD
Ibandronate—Asthenia—Doxorubicin—kidney cancer	0.000135	0.000143	CcSEcCtD
Ibandronate—Pruritus—Doxorubicin—kidney cancer	0.000133	0.000141	CcSEcCtD
Ibandronate—Diarrhoea—Doxorubicin—kidney cancer	0.000129	0.000136	CcSEcCtD
Ibandronate—Dizziness—Doxorubicin—kidney cancer	0.000125	0.000132	CcSEcCtD
Ibandronate—Vomiting—Doxorubicin—kidney cancer	0.00012	0.000126	CcSEcCtD
Ibandronate—Rash—Doxorubicin—kidney cancer	0.000119	0.000125	CcSEcCtD
Ibandronate—Dermatitis—Doxorubicin—kidney cancer	0.000119	0.000125	CcSEcCtD
Ibandronate—Headache—Doxorubicin—kidney cancer	0.000118	0.000125	CcSEcCtD
Ibandronate—Nausea—Doxorubicin—kidney cancer	0.000112	0.000118	CcSEcCtD
